Literature DB >> 22330685

Breast Cancer: Blocking both driver and escape pathways improves outcomes.

Mothaffar F Rimawi, C Kent Osborne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22330685     DOI： 10.1038/nrclinonc.2012.9

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

3.  Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

Authors:  Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; Nancy E Davidson; Charles E Geyer; Silvana Martino; Eleftherios P Mamounas; Peter A Kaufman; Norman Wolmark
Journal:  J Clin Oncol       Date:  2011-07-18       Impact factor: 44.544

4.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

5.  Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.

Authors:  Mothaffar F Rimawi; Lisa S Wiechmann; Yen-Chao Wang; Catherine Huang; Ilenia Migliaccio; Meng-Fen Wu; Carolina Gutierrez; Susan G Hilsenbeck; Grazia Arpino; Suleiman Massarweh; Robin Ward; Robert Soliz; C Kent Osborne; Rachel Schiff
Journal:  Clin Cancer Res       Date:  2010-12-07       Impact factor: 12.531

Review 6.  Mechanisms of endocrine resistance in breast cancer.

Authors:  C Kent Osborne; Rachel Schiff
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

7.  Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.

Authors:  Ritwik Ghosh; Archana Narasanna; Shizhen Emily Wang; Shuying Liu; Anindita Chakrabarty; Justin M Balko; Ana María González-Angulo; Gordon B Mills; Elicia Penuel; John Winslow; Jeff Sperinde; Rajiv Dua; Sailaja Pidaparthi; Ali Mukherjee; Kim Leitzel; Wolfgang J Kostler; Allan Lipton; Michael Bates; Carlos L Arteaga
Journal:  Cancer Res       Date:  2011-02-15       Impact factor: 12.701

8.  Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

Authors:  Chad J Creighton; Suleiman Massarweh; Shixia Huang; Anna Tsimelzon; Susan G Hilsenbeck; C Kent Osborne; Jiang Shou; Luca Malorni; Rachel Schiff
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

9.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321
  9 in total
  8 in total

1.  Fuel, electricity, ER and HER2--a hybrid-car model of breast cancer.

Authors:  Shigehira Saji; Fumiaki Sato; Naoto T Ueno
Journal:  Nat Rev Clin Oncol       Date:  2012-06-05       Impact factor: 66.675

2.  Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells.

Authors:  Chun Chen; William T Baumann; Robert Clarke; John J Tyson
Journal:  FEBS Lett       Date:  2013-08-28       Impact factor: 4.124

3.  Mammalian target of rapamycin (mTOR) inhibitors and combined chemotherapy in breast cancer: a meta-analysis of randomized controlled trials.

Authors:  Longwei Qiao; Yuting Liang; Ranim R Mira; Yaojuan Lu; Junxia Gu; Qiping Zheng
Journal:  Int J Clin Exp Med       Date:  2014-10-15

4.  Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer.

Authors:  Chun Chen; William T Baumann; Jianhua Xing; Lingling Xu; Robert Clarke; John J Tyson
Journal:  J R Soc Interface       Date:  2014-05-07       Impact factor: 4.118

Review 5.  Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546

6.  Severe everolimus-induced steatohepatis: a case report.

Authors:  Gisela Schieren; Edwin Bölke; Axel Scherer; Andreas Raffel; Peter Arne Gerber; Patric Kröpil; Matthias Schott; Jackson Hamilton; Anne Hayman; Wolfram Trudo Knoefel; Wilfried Budach; Christiane Matuschek
Journal:  Eur J Med Res       Date:  2013-07-03       Impact factor: 2.175

7.  Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.

Authors:  Pasquale Sansone; Claudio Ceccarelli; Marjan Berishaj; Qing Chang; Vinagolu K Rajasekhar; Fabiana Perna; Robert L Bowman; Michele Vidone; Laura Daly; Jennifer Nnoli; Donatella Santini; Mario Taffurelli; Natalie N C Shih; Michael Feldman; Jun J Mao; Christopher Colameco; Jinbo Chen; Angela DeMichele; Nicola Fabbri; John H Healey; Monica Cricca; Giuseppe Gasparre; David Lyden; Massimiliano Bonafé; Jacqueline Bromberg
Journal:  Nat Commun       Date:  2016-02-09       Impact factor: 14.919

8.  Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.

Authors:  Leonardo Mirandola; Elisa Pedretti; Jose A Figueroa; Raffaella Chiaramonte; Michela Colombo; Caroline Chapman; Fabio Grizzi; Federica Patrinicola; W Martin Kast; Diane D Nguyen; Rakhshanda Layeequr Rahman; Naval Daver; Peter Ruvolo; Sean M Post; Robert S Bresalier; Maurizio Chiriva-Internati
Journal:  Oncotarget       Date:  2017-08-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.